Author:
Bernstein David I.,Epstein Tolly G.
Abstract
Subcutaneous allergen immunotherapy (SCIT) is a unique treatment option for managing patients with allergic rhinitis, asthma, atopic dermatitis, and stinging insect allergy. Although systemic reactions to allergen injections are rare, near-fatal, and fatal anaphylactic reactions can
occur. Patients with asthma are at greatest risk for more severe reactions as are those with previous systemic reactions. Treating allergists should institute best clinical practices to prevent and manage severe systemic reactions to SCIT, including the following: (1) prescreening patients
with asthma for recent increases in asthma symptoms, (2) not prescribing SCIT to patients with severe and uncontrolled asthma, (3) instituting clinic protocols to prevent dosing errors, (4) considering modifying allergen doses during peak allergy seasons in patients at high risk, (5) instituting
measures that require all patients on SCIT to be observed for at least 30 minutes after injections, and (6) regular training of all clinical staff in the recognition and expeditious treatment of anaphylaxis.
Publisher
Oceanside Publications Inc.
Subject
Pulmonary and Respiratory Medicine,General Medicine,Immunology and Allergy
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety of allergen immunotherapy in children;Current Opinion in Allergy & Clinical Immunology;2023-10-17
2. Cluster immunotherapy;Annals of Allergy, Asthma & Immunology;2023-05
3. Allergen immunotherapy and shared decision-making;Allergy and Asthma Proceedings;2022-07-01
4. Venom allergen immunotherapy;Allergy and Asthma Proceedings;2022-07-01
5. United States Pharmacopeia guidance for compounding of allergenic extracts for allergen immunotherapy;Allergy and Asthma Proceedings;2022-07-01